Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ocugen ( (OCGN) ) has issued an announcement.
On July 1, 2025, Ocugen, Inc. received a notice from Nasdaq granting an additional 180 days to comply with the minimum bid price requirement of $1.00 per share, crucial for maintaining its listing on the Nasdaq Capital Market. Previously, on December 31, 2024, the company was informed of non-compliance, and it now has until December 29, 2025, to meet the criteria or face potential delisting, with the option to appeal if necessary.
The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s stock score reflects financial struggles balanced by strategic growth initiatives. The company’s weak financial foundation and valuation challenges are offset by promising gene therapy advancements and positive corporate events.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Average Trading Volume: 5,621,099
Technical Sentiment Signal: Hold
Current Market Cap: $287.4M
See more insights into OCGN stock on TipRanks’ Stock Analysis page.